4/18/2024  4:07:18 PM Chg. +1.64 Volume Bid4/18/2024 Ask4/18/2024 Market Capitalization Dividend Y. P/E Ratio
165.84USD +1.00% 19,285
Turnover: 3.18 mill.
165.47Bid Size: 120 181.77Ask Size: 100 292.86 bill.USD 3.61% 60.73

Business description

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

Management board & Supervisory board

Richard A. Gonzalez
Management board
Scott T. Reents, Carrie Strom, Dr. Azita Saleki-Gerhardt, Jeffrey R. Stewart, Perry C. Siatis, Rae L. Livingston, Robert A. Michael, Timothy J. Richmond, Kevin Buckbee, Nicholas Donoghoe, Tracie Haas, Thomas Hudson, Greg Miley, Elaine K. Sorg
Supervisory board
Richard A. Gonzalez, Brett J. Hart, Edward J. Rapp, Frederick H. Waddell, Glenn F. Tilton, Melody B. Meyer, Rebecca B. Roberts, Robert J. Alpern, Roxanne S. Austin, Thomas Freyman, William H.L. Burnside

Company data

Name: AbbVie Inc.
Address: 1 North Waukegan Road,North Chicago, Illinois 60064-6400, USA
Phone: +1-847-932-7900
Fax: -
E-mail: -
Internet: www.abbvie.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 96.70%
IPO date: 1/2/2013

Investor relations

Name: Liz Shea
IR phone: +1-847-935-2211
IR Fax: -
IR e-mail: liz.shea@abbvie.com

Company calendar

CW 17 | 4/26/2024 Interim Report 1st Quarter/3 Months
CW 20 | 5/15/2024 Dividend Payment

Main Shareholders

Vanguard Group Inc
Blackrock Inc.
State Street Corporation
JP Morgan Chase & Company
Capital International Investors
Geode Capital Management, LLC
Capital Research Global Investors
Morgan Stanley